摘要
抗血小板治疗在急性冠状动脉综合征(ACS)治疗中具有关键性作用。新型抗血小板药物替格瑞洛凭借其快速强效的特点,给临床ACS患者的抗栓治疗带来了一场革新,其疗效和安全性目前尚需进一步研究和评价。本文结合近期研究阐述替格瑞洛在ACS治疗中的应用现状。
In the treatment of patients with acute coronary syndrome （ACS）, antiplatelet therapy plays a key role. A new type of anti-platelet aggregation drug ticagrelor shows the fast onset and good effect in the treatment of patients with ACS, which has been recommended in many guidelines. Further researches still need to be done, although ticagrelor has brought antiplatelet therapy into a new phase. This paper reviews the application status and prospect of ticagrelor in ACS treatment.
出处
《世界临床药物》
CAS
2015年第11期784-788,共5页
World Clinical Drug
